M Pharmaceutical Inc. announced that it has entered into a manufacturing supply agreement with Rishena Co., Ltd., to manufacture the company's Trimtec gastric functional neurostimulation device. Under the terms of the agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharmaceutical for the North and South American markets. The devices will be fully programmable and rechargeable through an abdominal belt.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | +9,900.00% |
2018 | James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc | CI |
2018 | Callitas Health Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.53K | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- MPHMF Stock
- News Callitas Health Inc.
- Rishena Enters Into Manufacturing Supply Agreement for Production of Trimtec Gastric Stimulation Device